Figure Technology Solutions Inc. Class A Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Figure Technology Solutions Inc. Class A Common Stock trades at $28.25 (market cap $6.19B), while State Street SPDR S&P Biotech ETF trades at $154 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Figure Technology Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figure Technology Solutions Inc. Class A Common Stock for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FIGR | XBI | |
|---|---|---|
Market Cap | $6.19B | $10.11B |
Volume | 4,762,342 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $73.91 | $169.55 |
52-Week Low | $24.91 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $6.23B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.
Read more on FIGR →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →